BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
7/16/2012 - NAD Recommends VPX Discontinue Certain Claims for Medivin
The National Advertising Division has recommended that Vital Pharmaceuticals discontinue certain claims for its Medivin 100% Natural Liquid Vitamin & Mineral Delivery System, including claims that imply Medivin is more bioavailable than competing Animal Pak supplements. -
7/12/2012 - NAD Finds Nutrisystem’s “Pinned” Content is Testimonial in Nature, Requires Disclosures
The National Advertising Division, following its review of “Real Consumers. Real Success.” – a Pinterest board maintained by Nutrisystem, Inc. – has determined that the weight-loss success stories “pinned” to such boards represent consumer testimonials and require the complete disclosure of material information. -
7/11/2012 - NAD Recommends Bayer Discontinue Certain Claims for Citracal SR Following Challenge by Pfizer
The National Advertising Division has recommended that Bayer Healthcare discontinue certain claims for its Citracal Slow Release 1200 once-daily calcium supplement, including claims that state or imply that one dose of Citracal SR provides the same level of calcium as competing calcium supplements that require two daily doses. -
7/10/2012 - NAD Recommends Euro Pro Modify, Discontinue Certain Claims for ‘Shark Navigator Freestyle Vacuum’ Following Dyson Challenge
The National Advertising Division has recommended that Euro-Pro Operating LLC discontinue certain advertising claims made for the company’s Shark Navigator Freestyle Vacuum, including claims that the product “never loses cleaning power.” -
6/28/2012 - NAD Recommends Novartis Modify, Discontinue Certain Claims for ‘Sentinel’ Flea-Preventative
The National Advertising Division has recommended that Novartis Animal Health modify or discontinue certain performance and comparative claims for Sentinel Flavor Tabs, a flea-prevention medication for dogs. -
6/22/2012 - NAD Refers Advertising for Generix Labs’ ‘BiphedAdrene’ to FTC for Further Review
The National Advertising Division has referred advertising for BiphedAdrene, a product marketed Generix Laboratories, LLC, to the Federal Trade Commission for further review, following the company’s failure to provide a substantive response to an NAD inquiry. -
6/21/2012 - NAD Reviews ‘Strike-Through’ Claims at Booking.com, Expedia
The National Advertising Division, in separate challenges brought by Expedia and Booking.com, has recommended that “strike-through” pricing claims – where the original price of a one-night hotel stay is crossed out, but adjacent to the booking site’s sale price – require clear disclosures to assure consumers understand how original prices are calculated and whether there are limitations on the inventory of sale-price rooms. -
6/20/2012 - NAD Finds i-Health Can Support Claims for ‘BrainStrong’ DHA Supplement for Children
The National Advertising Division has determined that i-Health, Inc., can support certain advertising claims for the BrainStrong DHA supplements for young children, including that claim that the product “supports brain development and function.”
-
6/14/2012 - NAD Recommends Discover More Clearly Disclose Limitations on Cash-Back Promotions
The National Advertising Division has recommended that Discover Financial Services LLC either more clearly disclose the terms of its “5%” and “1%” cash-back programs or discontinue the advertising claims. -
6/13/2012 - NAD Recommends Ranir Modify, Discontinue Certain Claims for ‘Abridge’ Cold-Sore Treatment
The National Advertising Division Claims has recommended that Ranir, LLC, the maker of cold-sore treatment Abridge, modify or discontinue certain claims made for the product on its packaging, including claims related to speed of healing and “clinical strength.”